|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:ergoline_derivative
gptkb:dopamine_agonist
|
|
gptkbp:approvedBy
|
1988 (US)
|
|
gptkbp:ATCCode
|
N04BC02
|
|
gptkbp:brand
|
Permax
Prascend
|
|
gptkbp:CASNumber
|
66104-23-2
|
|
gptkbp:contraindication
|
cardiac valvulopathy
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
27 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C19H26N2S
|
|
gptkbp:hasSMILES
|
CN(C)CCCN1C2=CC=CC=C2C3=C1C=CC(=C3)SCC
|
|
gptkbp:legalStatus
|
withdrawn in US and EU
|
|
gptkbp:mechanismOfAction
|
dopamine receptor agonist
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
314.49 g/mol
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
47807
43513
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fibrosis
valvular heart disease
|
|
gptkbp:synonym
|
Pergolida
Pergolide mesylate
|
|
gptkbp:UNII
|
QX9Y1J6CZ1
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
equine Cushing's disease
pituitary pars intermedia dysfunction in horses
|
|
gptkbp:usedInVeterinaryMedicine
|
yes
|
|
gptkbp:withdrawn
|
gptkb:European_Union
gptkb:United_States
2007
|
|
gptkbp:bfsParent
|
gptkb:N04BB
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pergolide
|